Clinical Trial Update: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata [Phase 3]

View source ↗

Summary

Phase 3 study of baricitinib in adults with severe or very severe alopecia areata completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alopecia Areata | Phase 3 | Status: COMPLETED | Results posted: 2024-05-14